On November 8, 2022,Taysha Gene Therapies, Inc. closed the transaction. The company received $50 million in its final tranche.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.14 USD | +0.96% | +24.11% | +77.40% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,493 JPY | -1.35% | -2.29% | 17.66B | ||
3.14 USD | +0.96% | +24.11% | 582M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.40% | 582M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.